Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gossamer Bio, Inc. Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) October 07, 2024 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024 August 26, 2024 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update August 12, 2024 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference May 14, 2024 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update May 07, 2024 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications May 06, 2024 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine May 03, 2024 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors March 12, 2024 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update March 05, 2024 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) January 08, 2024 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023 December 13, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) December 05, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Appoints Bob Smith as Chief Commercial Officer December 05, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors November 29, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update November 09, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs October 03, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023 September 07, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update August 08, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results July 24, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces $212 Million Private Placement Financing July 20, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference May 18, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update May 09, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update March 17, 2023 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH December 06, 2022 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update November 03, 2022 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update August 09, 2022 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces $120 Million Private Placement Financing July 13, 2022 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH June 09, 2022 From Gossamer Bio, Inc. Via Business Wire Tickers GOSS Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
